The European Medicines Agency has issued for consultation its draft opinion on a proposed framework that explains how drug and device companies can design patient preference studies to support their use in regulatory and health technology assessment (HTA) decision-making.
The framework was developed by PREFER (Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle), a research project under the Innovative Medicines Initiative (IMI), which is a public-private partnership between the